NanoViricides Inc. (NNVC) stock prices surged by 14.50% around the time market trading commenced on September 14th, 2021. This brought the price per share up to USD$4.66 early on in the trading day.
NNVC Stock’s Licensing Completion
September 14th, 2021 saw NNVC stock announce the completion of the process of licensing the human Coronavirus field for drug development and commercialization from TheraCout Pharma Inc. The global leader in nanomedicines against viruses executed a license agreement on September 8th, 2021. This agreement was for the field, consisting of anti-viral treatments for the global coronavirus pandemic. These treatments were derived from human infections, resulting in the development of oral and pediatric drugs to fight Covid-19. The company’s proprietary treatments were designed to be effective against most variants of the virus.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Scope of Licensing
The licensed field is inclusive of antiviral drugs to treat the Covid-19 virus and its variants that have devastated the world for over a year. The license did not elicit an upfront cash payment and terms of compensation were commensurate with previous licenses. NNVC stock is facilitating the development of NV-CoV-2- and NV-CoV-2-R towards human clinical trials. The company has almost completed the essential preclinical work required to facilitate this progression.
Efficacy of NNVC Stock’s Drugs
NNVC’ stock’s broad-spectrum anti-coronavirus drugs are believed to continue to be effective despite the mutation of the virus. These mutations have hitherto resulted in several variants of concern. These variations have negatively impacted the antibody protection afforded by vaccines and the effectiveness of antibody drugs. The company’s unique anti-viral nanomachine technology manages to circumvent these challenges.
The company’s covid-19 drugs are also believed to be suitable for use in a pediatric context. Accordingly, NNVC stock plans to include pediatric cohorts into clinical trials at appropriate stages. The possibility of pediatric use of the drugs is based on the stellar safety profile indicated by animal studies. Pediatric infections and their severity have continued to increase as variants of Covid-19 continue to evolve.
Future Outlook for NNVC Stock
With the world hurtling towards universal immunizations, NNVC stock is poised to capitalize on the burgeoning market. The company is keen to spearhead the commercialization and proliferation of its proprietary treatments. Current and potential investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value.